PT004

PT004 is an early-stage drug candidate being developed by PulmoSIM Therapeutics for the treatment of respiratory diseases. It is currently in the preclinical or drug discovery phase. The candidate was identified using PulmoSIM's proprietary PRIMES (Platform for Rapid Identification of MEchanism of Action and Synergies) platform, which integrates machine learning and virtual patient models to repurpose and reformulate existing drugs for rare and progressive pulmonary conditions. While the specific molecular target and primary indication for PT004 have not been publicly disclosed, the company's broader pipeline focuses on high-unmet-need areas such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).